By: ELIZABETH MECHCATIE, Rheumatology News Digital Network
Major Finding: Evidence of inflammation on spinal MRIs of patients with ankylosing spondylitis (AS) was associated with a 1.5- to 2-fold increased risk of new syndesmophyte formation at the vertebral sites of inflammation 2 years later, which was statistically significant. But the growth of syndesmophytes that were present at vertebral sites at baseline was not associated with evidence of inflammation on MRIs.
Data Source: A study using a random sample of patients enrolled in ASSERT (AS Study for the Evaluation of Recombinant Infliximab Therapy), a randomized controlled study published in 2005 that compared infliximab to placebo in patients with active AS for 24 weeks, then followed patients until 102 weeks, during which time everyone was treated with infliximab.
Disclosures: One of the eight authors was supported by a grant from the Fundação para a Ciência e a Tecnologia (FCT); otherwise, the authors had no disclosures.
View on The News
AS-Related Needs More Study
Evidence of inflammation on spinal MRIs was "marginally predictive" of new syndesmophyte formation 2 years later at the vertebral sites where inflammation was observed, in a study of over 100 patients with ankylosing spondylitis.
However, growth of syndesmophytes that were present at vertebral sites at baseline was not associated with evidence of inflammation on MRIs, reported Dr. Désirée van der Heijde, of Leiden University Medical Center, Leiden, the Netherlands, and her associates, in the March issue of the Annals of the Rheumatic Diseases (Ann. Rheum. Dis. 2012;71:369-73).
|
STIR magnetic resonance image of the upper spine of a patient with ankylosing spondylitis, showing inflammatory lesions (bright signal) in multiple vertebral units.
|
"MRI inflammation in a vertebral unit slightly increases the likelihood of finding a new syndesmophyte in the same vertebral unit 2 years later, but does not predict the growth of already existing syndesmophytes," they wrote. The finding that most of the syndesmophytes grew in the vertebral units with no MRI evidence of inflammation suggests that "the relationship between MRI inflammation and syndesmophyte formation is not straightforward," they added.
The goal of the study was to address the association between inflammation of a vertebral unit (defined as "the region between two virtual lines through the middle of each vertebra") on MRI and the subsequent formation and growth of syndesmophytes, the excessive bone formation that represents the structural damage seen in ankylosing spondylitis (AS). The processes behind the formation of syndesmophytes in AS are not well understood and are not inhibited by treatment with tumor necrosis factor (TNF) blockers, despite the dramatic effects these agents have on inflammation, they noted.
They used data that included spinal MRI activity scores, from a random sample of people enrolled in ASSERT (AS Study for the Evaluation of Recombinant Infliximab Therapy), a 24-week study published in 2005 that compared infliximab to placebo in patients with active AS and followed patients in a open extension period up to 102 weeks, during which time everyone was treated with infliximab (Arthritis Rheum. 2005;52:582-91).
They analyzed information from 1,827 to 2,070 vertebral units from 177 to 183 patients, (the numbers varied, depending on the case definition and the reader of the MRI). MRI images of all 23 vertebral units of the spine – C2 to S1 – were scored on a scale of 0 to 3 (the presence of inflammation in a vertebral unit was defined as a score greater than 0), and a score from 4 to 6 if erosions were also evident.
After adjusting for possible confounders, the risk of developing a syndesmophyte in a vertebral unit with MRI evidence of inflammation was increased 1.5- to 2-fold, a statistically significant increase, they said.
Depending on the syndesmophyte definition used, the reader of the MRI, and the MRI case definition, 6%-32% of new syndesmophytes developed at the vertebral sites with evidence of active inflammation and 68%-94% of new syndesmophytes developed at the vertebral sites that had no evidence of active inflammation. Similar findings were observed for the syndesmophytes that were present at baseline: 0%-30% of the syndesmophytes that were present at baseline and grew were at sites of active inflammation, and 70%-100% of the syndesmophytes that grew "did so in vertebral units without inflammation," they reported.
View on The News
AS-Related Needs More Study
In an accompanying editorial titled, "Inflammation and Ankylosis: still an enigmatic relationship in spondyloarthritis," Dr. Rik Lories and Dr. Maxime Dougados referred to TNF-blocker therapy’s apparent lack of an effect on the structural progression of disease in patients with spondyloarthritis as a "clinical conundrum," noting that anti-TNF therapy slows progression in rheumatoid arthritis.
One hypothesis that has been proposed to address this issue is that inflammation, including TNF upregulation, triggers local damage and repair, which results in the formation of new bone and ankylosis, "establishing a causal coupling between inflammation" and the ankylosing process. Another hypothesis is that inflammation and new bone formation are caused by a "common trigger," but "further develop in a largely molecular independent way."
"Taken together, recent MRI studies on the structural progression of disease in spondyloarthritis and its relation to inflammation are another important step forward in our understanding of a disease that was neglected by most of the rheumatology research community for too long," they wrote, adding: "The complex nature of the disease and the many factors that have recently been implicated in playing a role in its onset and progression indicate that further research is needed" (Ann. Rheum. Dis. 2012;71:317-8).
Dr. Lories is K. U. Leuven is research professor at Universiteit Leuven (Belgium) and Dr. Dougados is professor of rheumatology at René Descartes University in Paris. They said they had no disclosures.
| Jun 6 - 9 Berlin, | EULAR (European League Against Rheumatism): 2012 Congress |
| Aug 23 - 25 San Francisco, CA | University of California, San Francisco (UCSF): Rheumatology Board Review and Clinical Update |
| Sep 2 - 5 Copenhagen, | Scandinavian Congress of Rheumatology (SCR) |
| Sep 28 - 29 Newport Beach, CA | 5th Annual Perspectives in Rheumatic Diseases presented by Rheumatology News, Internal Medicine News & Family Practice News |
| Nov 9 - 14 Washington, DC | American College of Rheumatology (ACR): Annual Scientific Meeting |
| Nov 14 - 17 Prague, | Connective Tissue Oncology Society (CTOS): Annual Meeting |
| Jan 26 - Feb 1 , | American College of Rheumatology (ACR): Winter Rheumatology Symposium |
| Feb 6 - 9 Maui, HI | Rheumatology Winter Clinical Symposium 2013 |
| Feb 13 - 16 Ottawa, | Canadian Rheumatology Association (CRA): Scientific Conference and Annual General Meeting |
| Sep 21 - 25 Natal, | 11th World Congress on Inflammation |